University of Münster
CRIS@UM
DE | EN

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibitionOpen Access

Kemper M; Evers G; Schulze AB; Sperveslage J; Schülke C; Lenz G; Herold T; Hartmann W; Schildhaus HU; Bleckmann A

Research article (journal) | Peer reviewed

Details about the publication

Journal: Oncotarget
Volume: 13
Page range: 1216-1216
Status: Published
Release year: 2022 (02/11/2022)
Language in which the publication is written: English
DOI: 10.18632/oncotarget.28293
Link to the full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448518/
Keywords: ALK; ALK inhibitors; KRAS; NSCLC; resistance mutations.

Authors from the University of Münster

Bleckmann, Annalen
Westdeutsches Tumorzentrum (WTZ) Netzwerkpartner Münster
Evers, Georg
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Hartmann, Wolfgang
Gerhard Domagk Institute of Pathology
Kemper, Marcel
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Lenz, Georg
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Schülke, Christoph
Clinic of Radiology
Schulze, Arik Bernard
Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A)
Sperveslage, Jan
Gerhard Domagk Institute of Pathology